1
|
Inokuchi T, Homma T, Kitasato Y, Akiyama M, Chikasue A, Nishii Y, Ban S, Adachi T, Sonezaki A, Masuda H, Kamei H, Takenaka M, Tanaka M, Okamoto M, Hoshino T. Oral Colchicine and Low-Dose Aspirin Combination Therapy for Non-elderly, Non-severe, Early Time From Onset, Adult Outpatients with Coronavirus Disease 2019 (COVID-19) during "The Fifth Pandemic Wave" in Japan. Kurume Med J 2024:MS7012003. [PMID: 38508737 DOI: 10.2739/kurumemedj.ms7012003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/22/2024]
Abstract
BACKGROUND Treatment with antiviral drugs for non-severe, early time from onset, adult outpatients with Coronavirus Disease 2019 (COVID-19) had not been established in 2021. However, some new variants of SARS-CoV-2 had caused rapid exacerbation and hospitalization among non-elderly outpatients with COVID-19, contributing to widespread crises within healthcare systems. METHODS From July to October 2021, we urgently assessed a therapeutic program using oral colchicine (1.0 mg loading dose, followed approximately half a day later by 0.5 mg twice daily for 5 days, and then 0.5 mg once daily for 4 days) and low-dose aspirin (100 mg once daily for 10 days), for non-elderly, non-severe, early time from onset, adult outpatients with COVID-19. To verify its effectiveness, we set loxoprofen as a control arm, and com parison of these two arms was performed. The primary outcomes were hospitalization, criticality, and death rates. RESULTS Thirty-eight patients (23 receiving colchicine and low-dose aspirin [CA]; 15 receiving loxoprofen [LO]) were evaluated. Hospitalization rate was lower in the CA group (1/23; 4.3%) than in the LO group (2/15; 13.3%); however, no significant difference was found between the two groups (p=0.34). No critical cases, deaths, or severe adverse events were found in either group. CONCLUSIONS Our CA regimen did not show superiority over LO treatment. However, our clinical experience should be recorded as part of community health care activities carried out in Kurume City against the unprece dented COVID-19 pandemic.
Collapse
Affiliation(s)
| | - Tomoki Homma
- Kurume Physicians Association (Kurume Naikaikai)
- Homma Cardiovascular Clinic
| | - Yasuhiko Kitasato
- Kurume Physicians Association (Kurume Naikaikai)
- JCHO Kurume General Hospital
| | | | | | - Yuuya Nishii
- JCHO Kurume General Hospital
- Division of Respirology, Neurology, and Rheumatology, Department of Medicine, Kurume University School of Medicine
| | - Shigeki Ban
- Kurume Physicians Association (Kurume Naikaikai)
- Ban Clinic
| | - Takeki Adachi
- Kurume Physicians Association (Kurume Naikaikai)
- Adachi Clinic
| | | | | | | | | | | | | | - Tomoaki Hoshino
- Division of Respirology, Neurology, and Rheumatology, Department of Medicine, Kurume University School of Medicine
| |
Collapse
|
2
|
Sakurai M, Takenaka M, Mitsui Y, Sakai Y, Morimoto M. Prednisolone improves hippocampal regeneration after trimethyltin-induced neurodegeneration in association with prevention of T lymphocyte infiltration. Neuropathology 2024; 44:21-30. [PMID: 37288771 DOI: 10.1111/neup.12926] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2022] [Revised: 05/10/2023] [Accepted: 05/12/2023] [Indexed: 06/09/2023]
Abstract
The endogenous regenerative capacity of the brain is quite weak; however, a regenerative reaction, the production of new neurons (neurogenesis), has been reported to occur in brain lesions. In addition, leukocytes are well known to infiltrate brain lesions. Therefore, leukocytes would also have a link with regenerative neurogenesis; however, their role has not been fully elucidated. In this study, we investigated leukocyte infiltration and its influence on brain tissue regeneration in a trimethyltin (TMT)-injected mouse model of hippocampal regeneration. Immunohistochemically, CD3-positive T lymphocytes were found in the hippocampal lesion of TMT-injected mice. Prednisolone (PSL) treatment inhibited T lymphocyte infiltration and increased neuronal nuclei (NeuN)-positive mature neurons and doublecortin (DCX)-positive immature neurons in the hippocampus. Investigation of bromodeoxyuridine (BrdU)-labeled newborn cells revealed the percentage of BrdU/NeuN- and BrdU/DCX-positive cells increased by PSL treatment. These results indicate that infiltrated T lymphocytes prevent brain tissue regeneration by inhibiting hippocampal neurogenesis.
Collapse
Affiliation(s)
- Masashi Sakurai
- Department of Veterinary Pathology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - Miki Takenaka
- Department of Veterinary Pathology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - Yuki Mitsui
- Department of Veterinary Pathology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| | - Yusuke Sakai
- Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan
| | - Masahiro Morimoto
- Department of Veterinary Pathology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan
| |
Collapse
|
3
|
Yamashita S, Takenaka M, Ohbayashi M, Kohyama N, Kurihara T, Sunaga T, Ishiguro H, Kogo M. Factors associated with readmission after long-term administration of tolvaptan in patients with congestive heart failure. Singapore Med J 2023; 0:369061. [PMID: 36751847 DOI: 10.4103/singaporemedj.smj-2021-348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Introduction We investigated the factors associated with readmission in patients with congestive heart failure (HF) receiving long-term administration of tolvaptan (TLV) to support treatment decisions for HF. Methods This retrospective cohort study included 181 patients with congestive HF who received long-term administration of TLV. Long-term administration of TLV was defined as the administration of TLV for 60 days or longer. The outcome was a readmission event for worsening HF within 1 year after discharge. Significant factors associated with readmission were selected using multivariate analysis. To compare the time to readmission using significant factors extracted in a multivariate analysis, readmission curves were constructed using the Kaplan-Meier method and analysed using the log-rank test. Results The median age was 78 years (range, 38-96 years), 117 patients (64.6%) were males, and 77 patients (42.5%) had a hospitalisation history of HF. Readmission for worsening HF within 1 year after long-term TLV treatment occurred in 62 patients (34.3%). In the multivariate analysis, estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 (odds ratio, 3.22; 95% confidence interval, 1.661-6.249; P = 0.001) was an independent significant factor. When eGFR at discharge was divided into two groups (eGFR < 30 vs. eGFR ≥ 30), readmission rates within 1 year were 53.3% vs. 25.4%, respectively (P = 0.001). Conclusion We revealed that eGFR was strongly associated with readmission in patients with HF who received long-term administration of TLV. Furthermore, we showed that eGFR is an important indicator in guiding treatment of HF in patients receiving TLV.
Collapse
Affiliation(s)
- Shoko Yamashita
- Department of Pharmacy, New Tokyo Hospital, Chiba; Division of Pharmacotherapeutics, Department of Clinical Pharmacy, School of Pharmacy, Showa University, Tokyo, Japan
| | - Miki Takenaka
- Division of Pharmacotherapeutics, Department of Clinical Pharmacy, School of Pharmacy, Showa University, Tokyo, Japan
| | - Masayuki Ohbayashi
- Division of Pharmacotherapeutics, Department of Clinical Pharmacy, School of Pharmacy, Showa University, Tokyo, Japan
| | - Noriko Kohyama
- Division of Pharmacotherapeutics, Department of Clinical Pharmacy, School of Pharmacy, Showa University, Tokyo, Japan
| | - Tatsuya Kurihara
- Division of Natural Medicine and Therapeutics, Department of Clinical Pharmacy, School of Pharmacy, Showa University, Tokyo, Japan
| | - Tomiko Sunaga
- Department of Hospital Pharmaceutics, School of Pharmacy, Showa University, Tokyo, Japan
| | - Hisaaki Ishiguro
- Department of Cardiology, New Tokyo Hospital, Chiba; Department of Cardiology, Ichinomiya Municipal Hospital, Aichi, Japan
| | - Mari Kogo
- Division of Pharmacotherapeutics, Department of Clinical Pharmacy, School of Pharmacy, Showa University, Tokyo, Japan
| |
Collapse
|
4
|
Sumitomo M, Nukaya T, Sugihara E, Takeda M, Nohara S, Tanishima S, Takenaka M, Zennami K, Takahara K, Shiroki R, Saya H. Evaluation of copy number and allelic imbalance of BRCA2 by next-generation sequencing to predict prognosis and drug sensitivity in prostate cancer. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00421-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
5
|
Li Q, Ho CP, Tang H, Okano M, Ikeda K, Takagi S, Takenaka M. Si racetrack optical modulator based on the III-V/Si hybrid MOS capacitor. Opt Express 2021; 29:6824-6833. [PMID: 33726194 DOI: 10.1364/oe.418108] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/22/2020] [Accepted: 02/11/2021] [Indexed: 06/12/2023]
Abstract
We have fabricated a Si racetrack optical modulator based on a III-V/Si hybrid metal-oxide-semiconductor (MOS) capacitor. The III-V/Si hybrid MOS optical phase shifter was integrated to a Si racetrack resonator with a coupling length of 200 µm and a coupling gap of 700 nm. The fabricated Si racetrack resonator demonstrated a small VπL of 0.059 Vcm. For 10-dB optical intensity modulation, the Si racetrack resonator showed a 60% smaller driving voltage than a Mach-Zehnder interferometer modulator with the same phase shifter, leading to a better balance between high energy efficiency and large modulation bandwidth.
Collapse
|
6
|
Okada T, Kohyama N, Takenaka M, Yamaguchi T, Kurihara T, Sakurai K, Miwa Y, Kogo M. Scoring Model to Predict a Low Disease Activity in Elderly Rheumatoid Arthritis Patients Initially Treated with Biological Disease-modifying Antirheumatic Drugs. Intern Med 2021; 60:1827-1834. [PMID: 34135268 PMCID: PMC8263196 DOI: 10.2169/internalmedicine.6251-20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Objective We aimed to develop a scoring model to predict a low disease activity (LDA) in elderly rheumatoid arthritis (RA) patients initially treated with biological disease-modifying antirheumatic drugs (bDMARDs). Methods This retrospective cohort study included 82 elderly RA patients who initially received bDMARDs. The outcome was an LDA after bDMARDs initiation. We developed a predictive formula for an LDA using a multivariate analysis, the accuracy of which was assessed by the area under the curve (AUC) of the receiver operating characteristic curves; the scoring model was developed using the formula. For each factor, approximate odds ratios were scored as an integer, divided into three groups based on the distribution of these scores. In addition, the scoring model accuracy was assessed. Results The mean age was 73.5±6.0 years old, and 86.6% were women. An LDA was achieved in 43 patients (52.4%). The predictive formula for an LDA was prepared using six factors selected for the multivariable analysis: the neutrophil-to-lymphocyte ratio (NLR), anemia, the 28-joint disease activity score with erythrocyte sedimentation rate (DAS28-ESR), serum level of matrix metalloproteinase-3 (MMP-3), diabetes mellitus (DM), and rheumatoid factor (RF). The AUC for the formula was 0.829 (95% confidence interval, 0.729-0.930). The odds ratios of the six factors were scored (DAS28-ESR and serum MMP-3=1 point, NLR, anemia, DM, and RF=2 points) and divided into three groups (≤4, 5-7, and ≥8). The high-score group (≥8) achieved a positive predictive value of 83%. Conclusion The scoring model accurately predicted an LDA in elderly RA patients initially treated with bDMARDs.
Collapse
Affiliation(s)
- Takahiro Okada
- Division of Pharmacotherapeutics, Department of Clinical Pharmacy, Showa University School of Pharmacy, Japan
| | - Noriko Kohyama
- Division of Pharmacotherapeutics, Department of Clinical Pharmacy, Showa University School of Pharmacy, Japan
| | - Miki Takenaka
- Division of Pharmacotherapeutics, Department of Clinical Pharmacy, Showa University School of Pharmacy, Japan
| | - Takashi Yamaguchi
- Division of Pharmacotherapeutics, Department of Clinical Pharmacy, Showa University School of Pharmacy, Japan
| | - Tatsuya Kurihara
- Division of Natural Medicine and Therapeutics, Department of Clinical Pharmacy, Showa University School of Pharmacy, Japan
| | - Kosuke Sakurai
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Japan
| | - Yusuke Miwa
- Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Japan
| | - Mari Kogo
- Division of Pharmacotherapeutics, Department of Clinical Pharmacy, Showa University School of Pharmacy, Japan
| |
Collapse
|
7
|
Hachisu M, Hashizume M, Kawai H, Hirano H, Kojima M, Fujiwara Y, Obuchi S, Kogo M, Ohbayashi M, Koyama N, Takenaka M, Ihara K. Finding prodromal frailty in a community-dwelling healthy older cohort by survey of BDNF or hand grip strength classified by BMI. ACTA ACUST UNITED AC 2020. [DOI: 10.31491/apt.2020.09.031] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
8
|
Takao Y, Toh U, Sakurai S, Saku S, Takenaka M, Akashi M, Sugihara R, Ogo E, Akagi Y. [Triple-Tracer Technique of Sentinel Lymph Node Biopsy Using Blue Dye plus Radioisotope Combined with Real-Time Indocyanine Green(ICG)Fluorescence Imaging Procedures for Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy]. Gan To Kagaku Ryoho 2020; 47:1225-1227. [PMID: 32829360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
Clinical evidence has indicated that, after neo-adjuvant chemotherapy(NAC), sentinel node(SN)identification rates(IR) were lower and false-negative rates(FNR)were higher for patients(pts)with local advanced breast cancer(BC)than for pts with early stage BC who did not receive NAC. Our previous clinical trial indicated that the real-time indocyanin green (RT-ICG)fluorescence imaging technique could improve the diagnostic sensitivity and detection accuracy of sentinel node biopsy(SNB). Nine pts with histologically confirmed Stage ⅡA to ⅢB, T1-T3, N0-2, M0 BC were selected to receive NAC, and the standard surgeries were performed after NAC completion. The SNs were detected by using conventional procedures with the blue dye(indigo carmine)plus 99mTc radioisotope techniques combined with concurrent RT-ICG. Clinically positive nodes were diagnosed by the radiologists using axillary ultrasound, MRI, and/or CT scans. All pts provided written informed consent before surgery. The surgical SNB was guided via RT-ICG fluorescence under standard light conditions by using the HEMS imaging system as previously published. All pts underwent SNB followed by completion node dissection(CND). The IR and FNR were calculated by comparing the results of the SNB and the histopathology of the resection specimens obtained via CND. The IR and FNR for each procedure of SNB were, respectively, 35.3% and 41.7% when indigo carmine blue was used, 82.4% and 0 when ICG fluorescence was used, and 58.8% and 5% when RI was used. In contrast, the total calculation of the triple tracer showed that IR reached 100% and FNR was 0. These data suggest that IR and FNR of SNB might be improved in pts with BC treated with NAC by using the novel triple tracer technique.
Collapse
Affiliation(s)
- Yuko Takao
- Dept. of Surgery, Kurume University School of Medicine
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Toh U, Saku S, Takao Y, Sakurai S, Takenaka M, Shichijo S, Itoh K, Akagi Y. Abstract P5-04-21: Analysis of serum immune biomarkers for response to therapeutic personalized peptide vaccination in patients with metastatic breast cancer. Cancer Res 2020. [DOI: 10.1158/1538-7445.sabcs19-p5-04-21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: Our results from the previous clinical trials using personalized peptide vaccines (PPV) combined conventional chemo-hormonal therapies have confirmed the potential for clinical benefit in patients who had higher IgG antibody and/or CTL response to the immunized PPV (SABCS 2018 U Toh etc.). The aim of this study is to evaluate the association between the serum immunologic factors including cytokines, haptoglobin (HP), B-cell activating factor (BAFF) etc. and the clinical outcome of patients(pt) with metastatic breast cancer (mBC) who treated by personalized peptide vaccines (PPV). Methods: Peripheral blood samples from 57 pts and 52 pts obtained before and after the vaccination of PPV, respectively. Serum HP and IL-6 were analyzed by ELISA(R&D Systems, Life Technologies)and bead-based multiplex assays(Luminex 200 system)were performed for GM-CSF,IFN-γ,TNF-α, BAFF, TGF-β, IFNγ-induced protein 10(IP-10), IL-1β, IL-2,-4,-5,-8, -10. The association between each factor and clinical outcome was statistically evaluated. Results: Pt’s group (n=28) with low BAFF and high HP level (>544 pg/ml), high IFN-γ and high HP level or low IL-8 and high HP level before PPV treatment showed a significantly shorter median survival time (MST; p=0.015;0.068;0.002, respectively). There was no difference in high BAFF, low IFN-γ or high IL-8 level group(n=29). In contrast, pt’s group with low serum level of IL-10, GM-CSF, IL-5, IL-4 and low HP level (<544 pg/ml MV) after PPV treatment associated with significantly shorter MST (p=0.002; 0.001; 0.001; <0.001, respectively). Conclusions: The combination of serum levels of HP and BAFF, IFN-γ or cytokines of IL-8, -10, - 5, -4 might be useful prognostic biomarkers for mBC pts receiving PPV therapy.
Citation Format: Uhi Toh, Shuko Saku, Yuko Takao, Sayaka Sakurai, Miki Takenaka, Shigeki Shichijo, Kyogo Itoh, Yoshito Akagi. Analysis of serum immune biomarkers for response to therapeutic personalized peptide vaccination in patients with metastatic breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P5-04-21.
Collapse
Affiliation(s)
- Uhi Toh
- Schl of Medicine, Kurume University, Kurume, Japan
| | - Shuko Saku
- Schl of Medicine, Kurume University, Kurume, Japan
| | - Yuko Takao
- Schl of Medicine, Kurume University, Kurume, Japan
| | | | | | | | - Kyogo Itoh
- Schl of Medicine, Kurume University, Kurume, Japan
| | | |
Collapse
|
10
|
Toh U, Okabe M, Takao Y, Tanaka Y, Shigaki T, Takenaka M, Iwakuma N, Sudo T, Yamada A, Shichijo S, Itoh K, Akagi Y. Abstract P4-06-06: Comparison of the immunological and clinical effect of personalized peptide vaccination for patients with breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-06-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Selected therapeutic personalized peptide vaccines (PPV) were effective for boosting anticancer immune response that was associated with the clinical outcome as a prognostic factor for metastatic recurrent breast cancer (mrBC) 1-2. In this study, we investigated the immunological and clinical effect of PPV as the prophylactic cancer vaccine for non-recurrent but high-risk BC (nrhrBC) patients (pts), and we compared it's features to those of the mrBC pts who had active cancers or became resistant to the standard therapies(TR-mrBC). Methods: Material and Patient eligibility criteria: The peptides were selected from the 31 PPVs according to the results of HLA typing and peptide-specific IgG titers. Pts with a histological diagnosis of BC and their HLA-A molecules should be each of -A2, A3, A11, A24, A26, A31 or A33. The clinical protocols were approved by the institutional review board. (UMIN000003081and 00000184400000). Treatment schedule: A maximum of 4 peptides was administrated as weekly for initial four vaccinations and as biweekly for further inoculations. The concomitant standard endocrine therapy and the chemo-endocrine therapy were available for nrhrBC pts after finishing the standard adjuvant chemotherapy, and for mrBC pts concurrently. Immune and clinical response assessment: Specific T-cell responses, IgG titers and cytokines were evaluated using by interferon (IFN)-γ ELISPOT, Luminex assay and ELISA system in every 6-8 vaccinations. Toxicity, clinical response and correlation with the immune responses were investigated. Results: 16 pts with nrhrBC, 41 pts with mrBC and 79 pts with TR-mrBC received median 18, 16 and 14 vaccines, respectively. After PPV therapies, peptide-specific IgG and CTLs increased significantly in a total of 47 (77%) and 37(60%) in nrhrBC pts, 102 (63%) and 98 (61%) in mrBC pts, and 150(53%) and 100 (42%) in TR-mrBC pts. Pts experienced Grade 1-3 skin reaction at injection site, no other grade 3 or 4 SAEs were associated with PPV but with the disease progression or combination therapy. The median time to progression (TTP) and overall survival (OS) were not reached in nrhrBC pts, 7.8 and 29 months in mrBC pts, and were 7.5 and 15.9 months in TR-mrBC pts, respectively. The peptide specific CTL response was correlated significantly with OS in nrhrBC pts and the IgG levels were associated with the better OS in either non TR-mrBC pts or TR-mrBC pts. High levels of IL-6, GM-CSF, IFN-g, IL-2 receptor, BAFF were associated with worse prognosis for pts with TR-mrBC. And high levels of GM-CSF and BAFF were associated with worse prognosis for pts with nrhrBC and mrBC, respectively. In contrast, High levels of IL-2 were associated with the better prognosis for pts with mrBC. Conclusion: This study indicated that immunological features of these three groups were different from each other with most potent PPV-induced immune boosting for nrhrBC pts. Pts with mrBC who had lower immune-suppressive cytokine levels had the better prognosis. These results suggested the PPV therapy could be effective for postoperative prophylactic vaccination in patients with nrhrBC. References: 1. Takahashi R, Toh U, et al. Breast Cancer Res. 2014; 2. Toh U, Okabe M, et al. THE BREAST 2015.
Citation Format: Toh U, Okabe M, Takao Y, Tanaka Y, Shigaki T, Takenaka M, Iwakuma N, Sudo T, Yamada A, Shichijo S, Itoh K, Akagi Y. Comparison of the immunological and clinical effect of personalized peptide vaccination for patients with breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-06-06.
Collapse
Affiliation(s)
- U Toh
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - M Okabe
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - Y Takao
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - Y Tanaka
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - T Shigaki
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - M Takenaka
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - N Iwakuma
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - T Sudo
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - A Yamada
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - S Shichijo
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - K Itoh
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| | - Y Akagi
- Kurume University School of Medicine, Kurume, Fukuoka, Japan; Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka, Japan; Cancer Vaccine Center, Kurume University, Kurume, Fukuoka, Japan
| |
Collapse
|
11
|
Li Q, Han JH, Ho CP, Takagi S, Takenaka M. Ultra-power-efficient 2 × 2 Si Mach-Zehnder interferometer optical switch based on III-V/Si hybrid MOS phase shifter. Opt Express 2018; 26:35003-35012. [PMID: 30650915 DOI: 10.1364/oe.26.035003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/02/2018] [Accepted: 12/14/2018] [Indexed: 06/09/2023]
Abstract
We have demonstrated an ultra-power-efficient 2 × 2 Si Mach-Zehnder interferometer optical switch with III-V/Si hybrid metal-oxide-semiconductor (MOS) phase shifters. The efficient low-loss phase modulation enables low-crosstalk and broadband switching in conjunction with multimode interference couplers consisting of tapered input and output ports. Owing to the negligible gate leakage current in the hybrid MOS capacitor, the power consumption required for switching is 0.18 nW, approximately 107 times smaller than that of a Si thermo-optic phase shifter. We also demonstrated a switching time of less than 20 ns. The III-V/Si hybrid MOS phase shifter is promising for fabricating large-scale Si photonic integrated circuits that require efficient, low-loss, and high-speed optical phase control.
Collapse
|
12
|
Yanaihara A, Michiba F, Ohgi S, Motomura K, Hirano A, Takenaka M, Yamashita M, Yanaihara T. Medical intervention during labor increases after in vitro fertilization pregnancy. CLIN EXP OBSTET GYN 2017. [DOI: 10.12891/ceog3809.2017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
|
13
|
Takenaka M, Iio A, Sato R, Sakamoto T, Kurumatani H. A Double-blind, Placebo-controlled, Multicenter, Prospective, Randomized Study of Beraprost Sodium Treatment for Cats with Chronic Kidney Disease. J Vet Intern Med 2017; 32:236-248. [PMID: 29131397 PMCID: PMC5787173 DOI: 10.1111/jvim.14839] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2016] [Revised: 06/09/2017] [Accepted: 08/22/2017] [Indexed: 02/02/2023] Open
Abstract
Background Chronic kidney disease (CKD) is a common progressive and irreversible disease in cats. The efficacy and safety of beraprost sodium (BPS) in cats with CKD have not been evaluated. Hypothesis/Objectives To evaluate the efficacy and safety of BPS in the treatment of cats with CKD, as compared to placebo. Animals Seventy‐four client‐owned cats with naturally occurring CKD. Methods Double‐blind, placebo‐controlled, multicenter, prospective, randomized trial. The cats received BPS (55 μg/cat) or a placebo PO q12 h for 180 days. The primary endpoint was prospectively defined as a change in the serum creatinine (sCr), serum phosphorus‐to‐calcium ratio or urine specific gravity (USG). Results The sCr increased significantly (P = 0.0030) in the placebo group (mean ± SD: 2.8 ± 0.7 to 3.2 ± 1.3 mg/dL) but not in the BPS group (2.4 ± 0.7 to 2.5 ± 0.7 mg/dL). The difference between the groups at day 180 was significant (0.8 mg/dL, 95% CI: 0.2 to 1.3 mg/dL, P = 0.0071). The serum phosphorus‐to‐calcium ratio was significantly (P = 0.0037) increased in the placebo group (0.46 ± 0.10 to 0.52 ± 0.21 mg/dL) but not in the BPS group (0.50 ± 0.08 to 0.51 ± 0.11 mg/dL). There was no significant change in the USG in either group. An adverse event judged as being treatment‐related included vomiting that occurred in 1 case in the placebo group. No clinically relevant change was observed in the CBC and other blood chemistry tests. Conclusions and Clinical Importance Beraprost sodium treatment was well tolerated and safe in cats with CKD. BPS inhibited the reduction in renal filtration function as measured by sCr increase.
Collapse
Affiliation(s)
- M Takenaka
- Animal Clinical Research Foundation, Kurayoshi, Tottori, Japan
| | - A Iio
- Toray Industries, Inc., Tokyo, Japan
| | - R Sato
- Department of Veterinary Medicine, Faculty of Agriculture, Iwate University, Morioka, Iwate, Japan
| | | | | | | |
Collapse
|
14
|
Chikaishi Y, Takenaka M, Kuroda K, Imanishi N, Tanaka F. V-009A CASE OF MEDIASTINAL TRACHEOSTOMY FOR TRACHEOSTENOSIS AFTER TRACHEOSTOMY WITH TRACHEOMALACIA BY MUCOPOLYSACCHARIDOSIS. Interact Cardiovasc Thorac Surg 2017. [DOI: 10.1093/icvts/ivx280.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
15
|
Chikaishi Y, Takenaka M, Kuroda K, Imanishi N, Tanaka F. V-039COMPLETE RESECTION OF THE ANTERIOR MEDIASTINAL TUMOUR THROUGH TOTAL ARCH REPLACEMENT AND PULMONARY ARTERY TRUNK RESECTION WITH A PERICARDIUM PATCH. Interact Cardiovasc Thorac Surg 2017. [DOI: 10.1093/icvts/ivx280.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
16
|
Chikaishi Y, Takenaka M, Kuroda K, Imanishi N, Tanaka F. P-271COMPLETE RESECTION OF THE PRIMARY LESION FOR STAGE IV NON-SMALL CELL LUNG CANCER. Interact Cardiovasc Thorac Surg 2017. [DOI: 10.1093/icvts/ivx280.271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Omae Y, Tanaka A, Takenaka M, Taruya A, Kimura K, Akagi H. P3981Prognostic value of transtricuspid pressure gradient assessment during ankle-flexing exercise echocardiography in patients with heart failure. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.p3981] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
Kusaka M, Okamoto M, Takenaka M, Sasaki H, Fukami N, Kataoka K, Ito T, Kenmochi T, Hoshinaga K, Shiroki R. Gene Expression Profiling of Peripheral Blood From Kidney Transplant Recipients for the Early Detection of Digestive System Cancer. Transplant Proc 2017; 49:1056-1060. [PMID: 28583526 DOI: 10.1016/j.transproceed.2017.03.059] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
BACKGROUND Kidney transplant recipients are at increased risk of developing cancer in comparison with the general population. To effectively manage post-transplantation malignancies, it is essential to proactively monitor patients. A long-term intensive screening program was associated with a reduced incidence of cancer after transplantation. This study evaluated the usefulness of the gene expression profiling of peripheral blood samples obtained from kidney transplant patients and adopted a screening test for detecting cancer of the digestive system (gastric, colon, pancreas, and biliary tract). STUDY DESIGN AND METHOD Nineteen patients were included in this study and a total of 53 gene expression screening tests were performed. The gene expression profiles of blood-delivered total RNA and whole genome human gene expression profiles were obtained. We investigated the expression levels of 2665 genes associated with digestive cancers and counted the number of genes in which expression was altered. A hierarchical clustering analysis was also performed. The final prediction of the cancer possibility was determined according to an algorithm. RESULTS The number of genes in which expression was altered was significantly increased in the kidney transplant recipients in comparison with the general population (1091 ± 63 vs 823 ± 94; P = .0024). The number of genes with altered expression decreased after the induction of mechanistic target of rapamycin (mTOR) inhibitor (1484 ± 227 vs 883 ± 154; P = .0439). No cases of possible digestive cancer were detected in this study period. CONCLUSION The gene expression profiling of peripheral blood samples may be a useful and noninvasive diagnostic tool that allows for the early detection of cancer of the digestive system.
Collapse
Affiliation(s)
- M Kusaka
- Department of Urology, Fujita-Health University School of Medicine, Toyoake, Aichi, Japan.
| | | | - M Takenaka
- Department of Urology, Fujita-Health University School of Medicine, Toyoake, Aichi, Japan
| | - H Sasaki
- Department of Urology, Fujita-Health University School of Medicine, Toyoake, Aichi, Japan
| | - N Fukami
- Department of Urology, Fujita-Health University School of Medicine, Toyoake, Aichi, Japan
| | | | - T Ito
- Department of Organ Transplant Surgery, Fujita-Health University, Toyoake, Aichi, Japan
| | - T Kenmochi
- Department of Organ Transplant Surgery, Fujita-Health University, Toyoake, Aichi, Japan
| | - K Hoshinaga
- Department of Urology, Fujita-Health University School of Medicine, Toyoake, Aichi, Japan
| | - R Shiroki
- Department of Urology, Fujita-Health University School of Medicine, Toyoake, Aichi, Japan
| |
Collapse
|
19
|
Oka S, Tanaka F, Takenaka M. V-012COMBINED TOTAL VERTEBRECTOMY FOR SUPERIOR SULCUS TUMOUR INVADING THE SPINE. Interact Cardiovasc Thorac Surg 2016. [DOI: 10.1093/icvts/ivw260.12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
20
|
Oka S, Tanaka F, Takenaka M. V-112TOTAL SUPERIOR VENA CAVA RESECTION COMBINED WITH TRACHEAL RESECTION FOR PRIMARY LUNG CANCER. Interact Cardiovasc Thorac Surg 2016. [DOI: 10.1093/icvts/ivw260.110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
21
|
Norimatsu Y, Yamaguchi T, Taira T, Abe H, Sakamoto H, Takenaka M, Yanoh K, Yoshinobu M, Irino S, Hirai Y, Kobayashi TK. Inter-observer reproducibility of endometrial cytology by the Osaki Study Group method: utilising the Becton Dickinson SurePath ™ liquid-based cytology. Cytopathology 2016; 27:472-478. [PMID: 27109167 DOI: 10.1111/cyt.12342] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/21/2016] [Indexed: 12/23/2022]
Abstract
OBJECTIVE The purpose of the present study was to evaluate the reproducibility of the cytological diagnosis of endometrial lesions by the Osaki Study Group (OSG) method of new cytological diagnostic criteria using BD SurePath™ (SP)-liquid-based cytology (LBC). METHODS This cytological classification using the OSG method consists of six categories: (i) normal endometrium (NE), (ii) endometrial glandular and stromal breakdown (EGBD), (iii) atypical endometrial cells, cannot exclude atypical endometrial hyperplasia or more (ATEC-A), (iv) adenocarcinoma including atypical endometrial hyperplasia or malignant tumour (Malignancy), (v) endometrial hyperplasia without atypia (EH) and (vi) atypical endometrial cells of undetermined significance (ATEC-US). For this study, a total 244 endometrial samplings were classified by two academic cytopathologists as follows: 147 NE cases , 36 EGBD cases , 47 Malignant cases, eight ATEC-A cases, two EH cases and four ATEC-US cases. To confirm the reproducibility of the diagnosis and to study the inter- and intra-observer agreement further, a second review round followed at 3-month intervals, which included three additional cytopathologists. RESULTS The inter-observer agreement of NE classes improved progressively from 'good to fair' to 'excellent', with values increasing from 0.70 to 0.81. Both EGBD and Malignancy classes improved progressively from 'good to fair' to 'excellent', with values increasing from 0.62-0.63 to 0.84-0.95, respectively. The overall intra-observer agreement between the first and the second rounds was 'good to fair' to 'excellent', with values changing from 0.79 to 0.85. All kappa improvements were significant (P < 0.0001). CONCLUSION In this study, it seemed that the use of the OSG method as the new diagnostic criteria for SP-LBC preparation, may be a valid method to improve the precision (reproducibility) of endometrial cytology.
Collapse
Affiliation(s)
- Y Norimatsu
- Faculty of Health Sciences, Department of Medical Technology, Ehime Prefectural University of Health Sciences, Ehime, Japan
| | - T Yamaguchi
- Department of Pathology, Kurume University Hospital, Fukuoka, Japan
| | - T Taira
- Department of Pathology, Kurume University Hospital, Fukuoka, Japan
| | - H Abe
- Department of Pathology, Kurume University Hospital, Fukuoka, Japan
| | - H Sakamoto
- Department of Cytology, The Tohkai Cytopathology Institute, Gifu, Japan
| | - M Takenaka
- Department of Cytology, The Tohkai Cytopathology Institute, Gifu, Japan
| | - K Yanoh
- Departments of Obstetrics and Gynecology and Pathology, JA Suzuka General Hospital, Mie, Japan
| | - M Yoshinobu
- Department of Diagnostic Pathology, Toyama Red Cross Hospital, Toyama, Japan
| | - S Irino
- Faculty of Health Sciences, Department of Nursing, Ehime Prefectural University of Health Sciences, Ehime, Japan
| | - Y Hirai
- Department of Obstetrics and Gynecology, Tokyo Women's Medical University, Tokyo, Japan
| | - T K Kobayashi
- Cancer Education and Research Center, Osaka University Graduate School of Medicine, Osaka, Japan
| |
Collapse
|
22
|
Yonezawa R, Yamamoto S, Takenaka M, Kage Y, Negoro T, Toda T, Ohbayashi M, Numata T, Nakano Y, Yamamoto T, Mori Y, Ishii M, Shimizu S. TRPM2 channels in alveolar epithelial cells mediate bleomycin-induced lung inflammation. Free Radic Biol Med 2016; 90:101-13. [PMID: 26600069 DOI: 10.1016/j.freeradbiomed.2015.11.021] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/01/2015] [Revised: 11/11/2015] [Accepted: 11/16/2015] [Indexed: 02/04/2023]
Abstract
Lung inflammation is a major adverse effect of therapy with the antitumor drug bleomycin (BLM). Transient receptor potential melastatin 2 (TRPM2) is a Ca(2+)-permeable channel that is activated by oxidative stress through the production of ADP-ribose. We herein investigated whether TRPM2 channels contributed to BLM-induced lung inflammation. The intratracheal instillation of BLM into wild-type (WT) mice increased the number of polymorphonuclear leukocytes (PMNs) and inflammatory cytokine levels in the lung. Increases in inflammatory markers in WT mice were markedly reduced in trpm2 knockout (KO) mice, which demonstrated that the activation of TRPM2 channels was involved in BLM-induced lung inflammation. The expression of TRPM2 mRNA was observed in alveolar macrophages, alveolar epithelial cells, and lung fibroblasts. Actually, TRPM2 protein was expressed in lung tissues. Of these, TRPM2 channels in epithelial cells were activated by the addition of H2O2 following a BLM pretreatment, resulting in the secretion of macrophage inflammatory protein-2 (MIP-2). The H2O2-induced activation of TRPM2 by the BLM pretreatment was blocked by the poly(ADP-ribose) polymerase (PARP) inhibitors PJ34 and 3-aminobenzamide. The accumulation of poly(ADP-ribose) in the nucleus, a marker for ADP-ribose production, was strongly induced by H2O2 following the BLM pretreatment. Furthermore, administration of PRAP inhibitors into WT mice markedly reduced recruitment of inflammatory cells and MIP-2 secretion induced by BLM instillation. These results suggest that the induction of MIP-2 secretion through the activation of TRPM2 channels in alveolar epithelial cells is an important mechanism in BLM-induced lung inflammation, and the TRPM2 activation is likely to be mediated by ADP-ribose production via PARP pathway. TRPM2 channels may be new therapeutic target for BLM-induced lung inflammation.
Collapse
Affiliation(s)
- Ryo Yonezawa
- Division of Physiology and Pathology, Department of Pharmacology, Toxicology and Therapeutics, Showa University School of Pharmacy, Tokyo, Japan; Division of Pharmacology, Faculty of Pharmaceutical Sciences, Teikyo Heisei University, 4-21-2 Nakano, Nakano-ku, Tokyo 164-8530, Japan
| | - Shinichiro Yamamoto
- Division of Pharmacology, Faculty of Pharmaceutical Sciences, Teikyo Heisei University, 4-21-2 Nakano, Nakano-ku, Tokyo 164-8530, Japan; Department of Molecular Cell Biology and Medicine, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan
| | - Miki Takenaka
- Division of Physiology and Pathology, Department of Pharmacology, Toxicology and Therapeutics, Showa University School of Pharmacy, Tokyo, Japan
| | - Yukiko Kage
- Division of Physiology and Pathology, Department of Pharmacology, Toxicology and Therapeutics, Showa University School of Pharmacy, Tokyo, Japan
| | - Takaharu Negoro
- Department of Pharmacogenomics, Showa University School of Pharmacy, Tokyo, Japan
| | - Takahiro Toda
- Laboratory of Pharmacology, Department of Clinical Pharmacy, Yokohama College of Pharmacy, Yokohama, Japan
| | - Masayuki Ohbayashi
- Division of Clinical Pharmacy, Department of Pharmacotherapeutics, Showa University School of Pharmacy, Tokyo, Japan
| | - Tomohiro Numata
- Department of Physiology, Graduate School of Medical Sciences, Fukuoka University, Fukuoka, Japan
| | - Yasuko Nakano
- Department of Pharmacogenomics, Showa University School of Pharmacy, Tokyo, Japan
| | - Toshinori Yamamoto
- Division of Clinical Pharmacy, Department of Pharmacotherapeutics, Showa University School of Pharmacy, Tokyo, Japan
| | - Yasuo Mori
- Department of Synthetic Chemistry and Biological Chemistry, Graduate School of Engineering, Kyoto University, Kyoto, Japan
| | - Masakazu Ishii
- Division of Physiology and Pathology, Department of Pharmacology, Toxicology and Therapeutics, Showa University School of Pharmacy, Tokyo, Japan
| | - Shunichi Shimizu
- Division of Physiology and Pathology, Department of Pharmacology, Toxicology and Therapeutics, Showa University School of Pharmacy, Tokyo, Japan; Division of Pharmacology, Faculty of Pharmaceutical Sciences, Teikyo Heisei University, 4-21-2 Nakano, Nakano-ku, Tokyo 164-8530, Japan; Laboratory of Pharmacology, Department of Clinical Pharmacy, Yokohama College of Pharmacy, Yokohama, Japan.
| |
Collapse
|
23
|
Imai E, Isaka Y, Akagi Y, Arai M, Moriyama T, Takenaka M, Kaneko T, Horio M, Ando A, Orita Y, Kaneda Y, Ueda N, Kamada T. Application of antisense oligodeoxynucleotides (ODNs) for the intervention of kidney disease. Antisense ODNs for transforming growth factor-beta-suppressed glomerulosclerosis in experimental glomerulonephritis. Contrib Nephrol 2015; 118:86-93. [PMID: 8744044 DOI: 10.1159/000425080] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Affiliation(s)
- E Imai
- First Department of Medicine, Osaka University School of Medicine, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Fujii T, Miwa K, Ushijima T, Matsunaga M, Fukahori M, Yuge K, Toh U, Iwakuma N, Takahashi R, Takahashi H, Takenaka M, Mishima M, Akagi Y, Kage M, Nakagawa S. HER2-targeted Therapeutic Strategies for HER2-positive Metastatic Breast Cancers. CCTR 2015. [DOI: 10.2174/157339471003150212111019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
25
|
Mishima M, Toh U, Iwakuma N, Takenaka M, Furukawa M, Akagi Y. Evaluation of contrast Sonazoid-enhanced ultrasonography for the detection of hepatic metastases in breast cancer. Breast Cancer 2014; 23:231-41. [PMID: 25143060 PMCID: PMC4773471 DOI: 10.1007/s12282-014-0560-0] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2014] [Accepted: 08/07/2014] [Indexed: 12/12/2022]
Abstract
Background The present study was aimed to evaluate the usefulness of contrast Sonazoid-enhanced ultrasonography (US) for the detection of hepatic metastases in breast cancer patients and compare the clinical efficacy and sensitivity of this technique with conventional contrast unenhanced B-mode US in follow-up examinations of breast cancer patients with liver metastasis. Methods We assessed a total of 84 hepatic tumors from 24 patients diagnosed with or suspected of having metastatic cancer. These hepatic nodules were diagnosed through imaging, including dynamic magnetic resonance imaging (MRI), contrast-enhanced computed tomography (CECT) scan, B-mode US or contrast Sonazoid-enhanced US (SEUS). Differences in the sensitivity between US and SEUS were compared using MR imaging, CECT, and follow-up imaging. Results A total of 79 nodules were diagnosed as metastatic tumors. The remaining nodules were diagnosed as benign tumors (hepatic hemangioma: n = 3; local fatty change: n = 2). SEUS precisely detected the presence or absence of hepatic tumors in the 24 patients examined, showing a sensitivity of 98.8 % (83 of 84 lesions) for total imaged solid liver lesions, with an accuracy of 98.7 % (78 of 79 lesions) for total metastatic breast cancer lesions. In contrast, conventional B-mode US imaging revealed hepatic tumor lesions at a sensitivity of 66.7 % (56 of 84 lesions) and an accuracy of 64.6 % (51 of 79 lesions), respectively. Furthermore, the false positive and false negative rates were, respectively, 6.33 and 29.1 % for B-mode US and 0 and 1.3 % for SEUS. Moreover, twenty-seven metastatic tumors and five benign lesions (3 hemangiomas and 2 focal fatty changes/sparings) were imaged using SEUS but not conventional B-mode US. Significant differences in diagnostic accuracy rates between contrast Sonazoid-enhanced US and conventional B-mode US were observed (Wilcoxon signed rank test: p = 0.0009). No severe adverse events occurred during SEUS after the administration of Sonazoid, except for a grade 1 skin reaction and nausea in one patient. Conclusion These results suggested that Sonazoid could be safely administrated to breast cancer patients with liver metastatic disease. Thus, contrast Sonazoid-enhanced US is a feasible and more effective method than B-mode US for the detection of hepatic metastasis, particularly for small metastatic breast cancer lesions less than 14 mm in diameter, showing significant high sensitivity and accuracy.
Collapse
Affiliation(s)
- Mai Mishima
- Department of Surgery, Kurume University School of Medicine, 67 Asahi-machi, 830-0011, Kurume, Fukuoka, Japan
| | - Uhi Toh
- Department of Surgery, Kurume University School of Medicine, 67 Asahi-machi, 830-0011, Kurume, Fukuoka, Japan.
| | - Nobutaka Iwakuma
- Department of Surgery, Kurume University School of Medicine, 67 Asahi-machi, 830-0011, Kurume, Fukuoka, Japan
| | - Miki Takenaka
- Department of Surgery, Kurume University School of Medicine, 67 Asahi-machi, 830-0011, Kurume, Fukuoka, Japan
| | - Mina Furukawa
- Department of Surgery, Kurume University School of Medicine, 67 Asahi-machi, 830-0011, Kurume, Fukuoka, Japan
| | - Yoshito Akagi
- Department of Surgery, Kurume University School of Medicine, 67 Asahi-machi, 830-0011, Kurume, Fukuoka, Japan
| |
Collapse
|
26
|
Takenaka M, Kusaka M, Fukami N, Ito T, Sasaki H, Shiroki R, Kenmochi T, Hoshinaga K. The Impact of Nocturia Was Not Noted On Quality of Life After Renal Transplantation. Transplantation 2014. [DOI: 10.1097/00007890-201407151-01903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
27
|
Kusaka M, Takenaka M, Fukami N, Sasaki H, Ito T, Kenmochi T, Shiroki R, Hoshinaga K. Serum High-Mobility Group Box-1 (HMGB-1) Kinetics After Kidney Transplantation From Donors After Cardiac Death. Transplantation 2014. [DOI: 10.1097/00007890-201407151-02232] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
28
|
Toh U, Iwakuma N, Mishima M, Takenaka M, Takahashi R, Furukawa M, Fujii T, Ogo E, Nakagawa S, Tanaka M, Sasada T, Itoh K, Akagi Y. Safety and immunologic efficacy of personalized multiple HLA class I-restricted peptide vaccines for breast cancer patients in the adjuvant setting. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.tps3130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Uhi Toh
- Department of Surgery, Kurume University Faculty of Medicine, Kurume, Japan
| | | | - Mai Mishima
- Kurume University Faculty of Medicine, Kurume, Japan
| | - Miki Takenaka
- Department of Surgery, Kurume University Faculty of Medicine, Kurume, Japan
| | - Ryuji Takahashi
- Department of Surgery, Kurume University School of Medicine, Kurume, Japan
| | - Mina Furukawa
- Department of Surgery, Kurume University Faculty of Medicine, Kurume, Japan
| | | | - Etsuyo Ogo
- Kurume University Faculty of Medicine, Kurume, Japan
| | | | - Maki Tanaka
- Kurume Social Insurance Daiichi Hospital, Kurume, Japan
| | - Tetsuro Sasada
- Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan
| | - Kyogo Itoh
- Kurume University School of Medicine, Kurume, Japan
| | - Yoshito Akagi
- Department of Surgery, Kurume University Faculty of Medicine, Kurume, Japan
| |
Collapse
|
29
|
Toh U, Iwakuma N, Mishima M, Takenaka M, Takahashi R, Koura K, Fujii T, Nakagawa S, Ogo E, Tanaka M, Sasada T, Itoh K, Shirouzu K. Abstract P5-01-05: Personalized peptide vaccines in combination with conventional chemo- or endocrine therapy for metastatic breast cancer: A single-arm phase II study. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p5-01-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Immunotherapy using multiple personalized peptide vaccines (PPV) has been reported to be effective for boosting anticancer immunity in patients (pts) with advanced prostate cancer and glioblastoma. The PPVs binding HLA-A2, A24, A3 family and A26 molecules were selected from 31 candidate peptides derived from various tumor associated antigens. Currently, we performed a phase II trial to evaluate the benefit of the PPVs in combination with conventional chemo-or endocrine therapy for pretreated metastatic breast cancer (MBC). Methods: Seventy-one pretreated pts had histologically confirmed measurable MBC and their HLA A molecules matched each of HLA-A2, A24, A26 and A3 family. Pre-vaccination plasma was measured for their IgG levels reactive to each of 31 peptides followed by administration subcutaneously of the four peptides at maximum showing higher levels of IgG in order with schedule of every 1-2 week. The concurrent conventional chemotherapy or endocrine therapy was available for the combination of PPVs. The primary endpoint was anti-tumor immunologic effect and safety, and the secondary endpoints were clinical responses and survival. Levels of IgG reactive to each of the 31 peptides in the pre- and post-treatment plasma at every 6 times of vaccination were measured using LUMNEX system. The CTL responses were simultaneously evaluated using ELISPOT method. Clinical response was evaluated by RECIST criteria. Results: Between May 2009 and December 2012, a total of 71 pts (Luminal-Her2- cases: 39; Her2+cases: 18; Triple negative(TN) cases:14) were enrolled in this study. The median duration of follow-up was 20.7 months. Concurrent chemotherapies (capecitabine, gemcitabine, eribulin, vinorelbine etc.) and endocrine therapies (aromatase inhibitor, toremifen or fulvestrant) were administered to 36 and 24 pts, respectively. Trastuzumab, Laptinib or Bevacizumab was simultaneously used for 13 pts. After 6th vaccination, the IgG reaction and CTL response were identified in 53 of 71 (74.6%) pts and 33 of 63 (52.3%) pts. There were no significant differences between TN cases and the other cases of MBC with regard to immunological humoral and/or cellular responses. No vaccine-related severe adverse events were observed. Clinical response rate of assessable 61 pts was 14.8% (CR 3, PR 6, SD 24, PD 28). The median PFS and OS were 7.6 m and 20.7 m, respectively. In contrast, the PFS and OS of luminal type, Her2 type or TN type were 12, 4.6 or 8.3 m and 24, 15 or 12 m. Conclusions: The phase II PPVs study for MBC demonstrated the promising response and safety, and further studies are essential to identify the clinical benefits of this novel therapy. Clinical trial information: UMIN000001482.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P5-01-05.
Collapse
Affiliation(s)
- U Toh
- Kurume University School of Medicine, Kurume, Japan; Social Insurance Kurume Daiichi Hospital, Kurume, Japan
| | - N Iwakuma
- Kurume University School of Medicine, Kurume, Japan; Social Insurance Kurume Daiichi Hospital, Kurume, Japan
| | - M Mishima
- Kurume University School of Medicine, Kurume, Japan; Social Insurance Kurume Daiichi Hospital, Kurume, Japan
| | - M Takenaka
- Kurume University School of Medicine, Kurume, Japan; Social Insurance Kurume Daiichi Hospital, Kurume, Japan
| | - R Takahashi
- Kurume University School of Medicine, Kurume, Japan; Social Insurance Kurume Daiichi Hospital, Kurume, Japan
| | - K Koura
- Kurume University School of Medicine, Kurume, Japan; Social Insurance Kurume Daiichi Hospital, Kurume, Japan
| | - T Fujii
- Kurume University School of Medicine, Kurume, Japan; Social Insurance Kurume Daiichi Hospital, Kurume, Japan
| | - S Nakagawa
- Kurume University School of Medicine, Kurume, Japan; Social Insurance Kurume Daiichi Hospital, Kurume, Japan
| | - E Ogo
- Kurume University School of Medicine, Kurume, Japan; Social Insurance Kurume Daiichi Hospital, Kurume, Japan
| | - M Tanaka
- Kurume University School of Medicine, Kurume, Japan; Social Insurance Kurume Daiichi Hospital, Kurume, Japan
| | - T Sasada
- Kurume University School of Medicine, Kurume, Japan; Social Insurance Kurume Daiichi Hospital, Kurume, Japan
| | - K Itoh
- Kurume University School of Medicine, Kurume, Japan; Social Insurance Kurume Daiichi Hospital, Kurume, Japan
| | - K Shirouzu
- Kurume University School of Medicine, Kurume, Japan; Social Insurance Kurume Daiichi Hospital, Kurume, Japan
| |
Collapse
|
30
|
Takahashi R, Toh U, Iwakuma N, Mishima M, Fujii T, Takenaka M, Koura K, Seki N, Kawahara A, Kage M, Ogo E, Shirouzu K. Treatment outcome in patients with stage III breast cancer treated with neoadjuvant chemotherapy. Exp Ther Med 2013; 6:1089-1095. [PMID: 24223627 PMCID: PMC3820806 DOI: 10.3892/etm.2013.1289] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2013] [Accepted: 08/22/2013] [Indexed: 11/05/2022] Open
Abstract
Despite the good responses of patients (pts) with stage III breast cancer to neoadjuvant chemotherapy (NAC), most eventually relapse and have a poor prognosis. We investigated the prognostic indicators in pts with stage III breast cancer treated with NAC, using epirubicin and/or docetaxel. A total of 22 women with stage III breast cancer underwent NAC between January 2005 and May 2011. The regimens of NAC comprised ED (epirubicin 60 mg/m2 and docetaxel 60 mg/m2) in 10 cases, FEC (fluorouracil 500 mg/m2, epirubicin 75-100 mg/m2 and cyclophosphamide 500 mg/m2) in 10 cases and EC (epirubicin 60 mg/m2 and cyclophosphamide 600 mg/m2) in two cases. Following four cycles of each regimen, a further four cycles of D (docetaxel 70 mg/m2) were undertaken in nine cases. Subsequent to the completion of NAC and surgery, we assessed the clinicopathological results and performed prognostic analyses. Statistical analyses concerning disease-free survival (DFS) or overall survival (OS) were conducted by a Cox proportional hazard model. The median survival time was 66 months and there were 12 distant metastases and two local recurrences. Multivariate analyses showed the number of metastatic axillary lymph nodes (ALNs) [hazard ratio (HR), 1.079; P=0.023] was correlated with DFS, while the Ki-67 labeling index (HR, 1.109; P=0.042) and the number of meta-static ALNs (HR, 1.087; P=0.023) were correlated with OS. In conclusion, even if pts with stage III breast cancer show good responses to NAC using epirubicin and/or docetaxel, the majority eventually relapse and have a poor prognosis. The Ki-67 labeling index and the number of involved ALNs are suggested as prognostic indicators in stage III breast cancer.
Collapse
Affiliation(s)
- Ryuji Takahashi
- Department of Surgery, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Takahashi H, Fujii T, Nakagawa S, Inoue Y, Akashi M, Toh U, Iwakuma N, Takahashi R, Takenaka M, Fukuma E, Shirouzu K. Usefulness of endoscopic breast-conserving surgery for breast cancer. Surg Today 2013; 44:2037-44. [PMID: 24150099 DOI: 10.1007/s00595-013-0767-2] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2013] [Accepted: 09/30/2013] [Indexed: 11/30/2022]
Abstract
PURPOSE We compared the safety, invasiveness and cosmetic outcomes between endoscopic breast-conserving surgery (endoscopic group) and surgery under direct vision (direct vision group) for treating breast cancer. METHODS We compared 100 cases of endoscopic surgery with 150 cases of direct vision surgery. The safety was evaluated in terms of the blood loss, length of the operation and presence or absence of complications, whereas the degree of invasiveness was assessed using preoperative and postoperative leukocyte counts, neutrophil counts, interleukin (IL-6) levels and fever. The cosmetic outcome was assessed on the basis of a breast evaluation by the medical staff and the patient's subjective satisfaction. RESULTS In both groups, serious postoperative complications were absent. No significant differences were observed in the leukocyte counts, neutrophil counts, IL-6 level or fever between the groups. An evaluation of the cosmetic outcomes by the staff showed a more favorable breast size, breast shape and scar condition in the endoscopic group. A significantly higher level of patient satisfaction was also observed in the endoscopic group. Postoperative local recurrence was absent. CONCLUSIONS The endoscopic approach showed comparable safety and invasiveness, and provided better postoperative cosmetic outcomes than direct vision surgery. Our results suggest that endoscopic breast-conserving surgery is a potentially useful surgical method for the treatment of breast cancer.
Collapse
Affiliation(s)
- Hiroki Takahashi
- Breast Care Center, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Yamaguchi R, Tanaka M, Tse GM, Yamaguchi M, Terasaki H, Nomura Y, Takenaka M, Naito Y, Akiba J, Yano H. Broad fibrovascular cores may not be an exclusively benign feature in papillary lesions of the breast: a cautionary note. J Clin Pathol 2013; 67:258-62. [DOI: 10.1136/jclinpath-2013-201749] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
33
|
Takenaka M, Akiba J, Kawaguchi T, Niizeki T, Arinaga-Hino T, Sata M, Nakashima O, Yano H, Kage M. Intrahepatic cholangiocarcinoma with sarcomatous change producing granulocyte-colony stimulating factor. Pathol Int 2013; 63:233-5. [DOI: 10.1111/pin.12051] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Miki Takenaka
- Department of Pathology; Kurume University School of Medicine; Kurume; Japan
| | - Jun Akiba
- Department of Pathology; Kurume University School of Medicine; Kurume; Japan
| | - Toshihiro Kawaguchi
- Division of Gastroenterology; Department of Medicine; Kurume University School of Medicine; Kurume; Japan
| | - Takashi Niizeki
- Division of Gastroenterology; Department of Medicine; Kurume University School of Medicine; Kurume; Japan
| | - Teruko Arinaga-Hino
- Division of Gastroenterology; Department of Medicine; Kurume University School of Medicine; Kurume; Japan
| | - Michio Sata
- Division of Gastroenterology; Department of Medicine; Kurume University School of Medicine; Kurume; Japan
| | - Osamu Nakashima
- Department of Clinical Inspection; Kurume University Hospital; Kurume; Japan
| | - Hirohisa Yano
- Department of Pathology; Kurume University School of Medicine; Kurume; Japan
| | - Masayoshi Kage
- Department of Diagnostic Pathology; Kurume University Hospital; Kurume; Japan
| |
Collapse
|
34
|
Takenaka M, Seki N, Toh U, Hattori S, Kawahara A, Yamaguchi T, Koura K, Takahashi R, Otsuka H, Takahashi H, Iwakuma N, Nakagawa S, Fujii T, Sasada T, Yamaguchi R, Yano H, Shirouzu K, Kage M. FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis. Mol Clin Oncol 2013; 1:625-632. [PMID: 24649219 PMCID: PMC3915667 DOI: 10.3892/mco.2013.107] [Citation(s) in RCA: 84] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2012] [Accepted: 04/05/2013] [Indexed: 12/04/2022] Open
Abstract
The forkhead box protein 3 (FOXP3) transcription factor is highly expressed in tumor cells as well as in regulatory T cells (Tregs). It plays a tumor-enhancing role in Tregs and suppresses carcinogenesis as a potent repressor of several oncogenes. The clinical prognostic value of FOXP3 expression has not yet been elucidated. In this study, immunohistochemistry was used to investigate the prognostic significance of FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes (TILs) in breast cancer patients. Of the 100 tumor specimens obtained from primary invasive breast carcinoma, 63 and 57% were evaluated as FOXP3+ tumor cells and as being highly infiltrated by FOXP3+ lymphocytes, respectively. Although FOXP3 expression in tumor cells was of no prognostic significance, FOXP3+ lymphocytes were significantly associated with poor overall survival (OS) (n=98, log-rank test P=0.008). FOXP3 exhibited a heterogeneous subcellular localization in tumor cells (cytoplasm, 31%; nucleus, 26%; both, 6%) and, although cytoplasmic FOXP3 was associated with poor OS (P= 0.058), nuclear FOXP3 demonstrated a significant association with improved OS (P=0.016). Furthermore, when patients were grouped according to their expression of tumor cytoplasmic FOXP3 and lymphocyte FOXP3, there were notable differences in the Kaplan-Meier curves for OS (P<0.001), with a high infiltration of FOXP3+ lymphocytes accompanied by a cytoplasmic FOXP3+ tumor being the most detrimental phenotype. These findings indicated that FOXP3 expression in lymphocytes as well as in tumor cells may be a prognostic marker for breast cancer. FOXP3 in tumor cells may have distinct biological activities and prognostic values according to its localization, which may help establish appropriate cancer treatments.
Collapse
Affiliation(s)
- Miki Takenaka
- Departments of Pathology, School of Medicine, Kurume University, Kurume, Fukuoka 830-0011, Japan ; ; Surgery, School of Medicine, Kurume University, Kurume, Fukuoka 830-0011, Japan
| | - Naoko Seki
- Research Center for Innovative Cancer Therapy, School of Medicine, Kurume University, Kurume, Fukuoka 830-0011, Japan
| | - Uhi Toh
- Surgery, School of Medicine, Kurume University, Kurume, Fukuoka 830-0011, Japan
| | - Satoshi Hattori
- Biostatistical Center, Kurume University, Kurume, Fukuoka 830-0011, Japan
| | - Akihiko Kawahara
- Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Fukuoka 830-0011, Japan
| | - Tomohiko Yamaguchi
- Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Fukuoka 830-0011, Japan
| | - Keiko Koura
- Departments of Pathology, School of Medicine, Kurume University, Kurume, Fukuoka 830-0011, Japan ; ; Surgery, School of Medicine, Kurume University, Kurume, Fukuoka 830-0011, Japan
| | - Ryuji Takahashi
- Surgery, School of Medicine, Kurume University, Kurume, Fukuoka 830-0011, Japan
| | - Hiroko Otsuka
- Surgery, School of Medicine, Kurume University, Kurume, Fukuoka 830-0011, Japan
| | - Hiroki Takahashi
- Surgery, School of Medicine, Kurume University, Kurume, Fukuoka 830-0011, Japan
| | - Nobutaka Iwakuma
- Surgery, School of Medicine, Kurume University, Kurume, Fukuoka 830-0011, Japan
| | - Shino Nakagawa
- Surgery, School of Medicine, Kurume University, Kurume, Fukuoka 830-0011, Japan
| | - Teruhiko Fujii
- Surgery, School of Medicine, Kurume University, Kurume, Fukuoka 830-0011, Japan ; ; Multidisciplinary Treatment Center, Kurume University Hospital, Kurume, Fukuoka 830-0011, Japan
| | - Tetsuro Sasada
- Department of Immunology, School of Medicine, Kurume University, Kurume, Fukuoka 830-0011, Japan
| | - Rin Yamaguchi
- Departments of Pathology, School of Medicine, Kurume University, Kurume, Fukuoka 830-0011, Japan
| | - Hirohisa Yano
- Departments of Pathology, School of Medicine, Kurume University, Kurume, Fukuoka 830-0011, Japan
| | - Kazuo Shirouzu
- Surgery, School of Medicine, Kurume University, Kurume, Fukuoka 830-0011, Japan
| | - Masayoshi Kage
- Research Center for Innovative Cancer Therapy, School of Medicine, Kurume University, Kurume, Fukuoka 830-0011, Japan ; ; Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Fukuoka 830-0011, Japan
| |
Collapse
|
35
|
Nagamine A, Takenaka M, Aomori T, Okada Y, Hiromura K, Nojima Y, Araki T, Nakamura T, Yamamoto K. Effect of genetic polymorphisms on effectiveness of low-dose azathioprine in Japanese patients with systemic lupus erythematosus. Am J Health Syst Pharm 2012; 69:2072-8. [DOI: 10.2146/ajhp120179] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Affiliation(s)
- Ayumu Nagamine
- Department of Pharmacy Gunma University Hospital, Showa-machi, Maebashi, Japan
| | - Miki Takenaka
- Department of Pharmacy Gunma University Hospital, Showa-machi, Maebashi, Japan
| | - Tohru Aomori
- Department of Clinical Pharmacology, Graduate School of Medicine, Gunma University, Showa-machi
| | - Yuko Okada
- Faculty of Pharmacy, Takasaki University of Health and Welfare, Nakaoorui-machi, Takasaki, Japan
| | | | | | | | | | - Koujirou Yamamoto
- Department of Clinical Pharmacology, Graduate School of Medicine, Gunma University
| |
Collapse
|
36
|
Takenaka M, Hayashi M, Suzuki I, Yamada Y, Takamatsu K, Kageyama M. Evaluation of a mirror-polishing technique for fluorocarbon polymer surfaces for reduction of contamination from containers used in ultratrace analysis. Anal Chem 2012; 69:972-6. [PMID: 21639235 DOI: 10.1021/ac960906g] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A mirror-polishing technique for fluorocarbon polymer surfaces using high-precision diamond cutting tools was developed. The goal of this technique was the reduction of ultratrace elemental analysis contamination levels of containers fabricated from such mirror-polished materials. Remarkably smooth inner surfaces with degrees of flatness of 0.1 μm peak-to-valley (PTV) for containers fabricated from mirror-polished PTFE materials were obtained, in contrast to degrees of surface flatness of more than 30 μm PTV for commercially available PTFE containers. (Here, PTV denotes the difference between the highest peak and deepest valley in a scanned area of 10 × 10 μm.) Extractable impurity levels for mirror-polished PTFE container surfaces were reduced by more than 1 order of magnitude relative to those of unpolished PTFE containers. The surface conditions of the PTFE containers were observed by atomic force and scanning electron microscopy. The microphotographs so obtained suggest that the degree of surface smoothness of the containers is proportional to their ultratrace metallic contamination levels.
Collapse
Affiliation(s)
- M Takenaka
- Research and Development Center, Toshiba Corporation, 1 Komukai, Toshiba-cho, Saiwai-ku, Kawasaki 210, Japan
| | | | | | | | | | | |
Collapse
|
37
|
Tiriveedhi V, Takenaka M, Ramachandran S, Gelman AE, Subramanian V, Patterson GA, Mohanakumar T. T regulatory cells play a significant role in modulating MHC class I antibody-induced obliterative airway disease. Am J Transplant 2012; 12:2663-74. [PMID: 22822907 PMCID: PMC3459183 DOI: 10.1111/j.1600-6143.2012.04191.x] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
The molecular mechanisms leading to the development of chronic lung allograft dysfunction following de novo development of antibodies to mismatched donor MHC remain undefined. We demonstrated that intrabronchial administration of antibodies to MHC class I resulted in induction of both innate and adaptive cellular immune responses characterized by a predominance of Th17 specific to lung associated self-antigens Kα1-tubulin and Collagen-V leading to the development of obliterative airway lesions (OAD), correlate of chronic rejection following human lung transplantation. To determine the role of regulatory T cells (Treg) in the pathogenesis of OAD, we administered anti-MHC class I to mice, in which Treg were depleted by conditional ablation of FoxP3+cells. Under this condition, we observed a threefold increase in pulmonary cellular infiltration, luminal occlusion and fibrous deposition when compared anti-MHC class I Ab administered mice maintaining FoxP3. OAD lesions were accompanied with enhanced accumulation of neutrophils along with self-antigen-specific Th17 and humoral responses. However, IL-17-blockade or adoptive transfer of Treg abrogated OAD. We conclude that Treg exerts a suppressive effect on anti-MHC induced IL-8-mediated neutrophil infiltration and innate immune responses that leads to inhibition of Th17 immune responses to lung associated self-antigens which is critical for development of OAD.
Collapse
Affiliation(s)
- V. Tiriveedhi
- Department of Surgery, Washington University School of Medicine, St Louis, MO, USA
| | - M. Takenaka
- Department of Surgery, Washington University School of Medicine, St Louis, MO, USA
| | - S. Ramachandran
- Department of Surgery, Washington University School of Medicine, St Louis, MO, USA
| | - A. E. Gelman
- Department of Surgery, Washington University School of Medicine, St Louis, MO, USA
| | - V Subramanian
- Department of Surgery, Washington University School of Medicine, St Louis, MO, USA
| | | | - T. Mohanakumar
- Department of Surgery, Washington University School of Medicine, St Louis, MO, USA
,Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA
| |
Collapse
|
38
|
Iwakuma N, Toh U, Grobmyer SR, Koura K, Takenaka M, Otsuka H, Takahashi R, Shirouzu K. Active targeting nanoparticle for breast cancer diagnosis and treatment. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.27_suppl.163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
163 Background: Breast cancer remains a major ongoing public health problem among women. Nanotechnology is the exciting field focused on man-made materials in the size range of 1-100 nanometers (nm). Nanoparticles (NPs) are on the scale of many cellular-level processes and hence are attractive for targeting breast cancer. Emerging nanotechnologies promise new approaches to early detection and treatment of breast cancer. Our group has reported Gold Speckled Silica NPs (GSS) as multimodal contrast agents for fluorescence, magnetic resonance and photoacoustic tomographic (PAT) imaging. The near infrared (NIR) optical absorption property of these particles makes them potentially useful for therapeutic applications such as thermal ablation of tumors. Fulfilling the promise of nanotechnologies for patients with metastatic breast cancer, necessitates delivery of nanomaterials to sites of breast cancer. Now we have focused on the cancer metabolism, we have recently developed active targeting NPs with surface functionalizing agent such as glucose conjugated NPs. We hypothesize that active targeting NPs is more incorporated into cancer cells compared to normal NPs. Methods: Human breast cancer cells, BT474, were incubated with active targeting NPs or normal NPs (as control). The tumor cell uptake was assessed using flow cytometry and fluorescence microscopy experiments. Results: Uptake of active targeting NPs was significantly higher than uptake of normal NPs. Conclusions: Active targeting NPs can be used as suitable targeting NPs for development of imaging agents for early diagnosis of breast cancer. Evolving bio-nanotechnologies such as active targeting NPs promise to enhance the early detection and non-invasive treatment of breast cancer.
Collapse
Affiliation(s)
| | - Uhi Toh
- Department of Surgery, Kurume University Faculty of Medicine, Kurume, Japan
| | | | - Keiko Koura
- Kurume University School of Medicine, Fukuoka, Japan
| | - Miki Takenaka
- Department of Surgery, Kurume University Faculty of Medicine, Kurume, Japan
| | | | - Ryuji Takahashi
- Department of Surgery, Kurume University Faculty of Medicine, Kurume, Japan
| | - Kazuo Shirouzu
- Department of Surgery, Kurume University Faculty of Medicine, Kurume, Japan
| |
Collapse
|
39
|
Takenaka M, Toh U, Otsuka H, Takahashi H, Iwakuma N, Nakagawa S, Fujii T, Yamaguchi R, Yano H, Shirouzu K, Kage M. Giant malignant phyllodes tumor: a case report. Kurume Med J 2012; 58:67-72. [PMID: 22251824 DOI: 10.2739/kurumemedj.58.67] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
We present a case of a 57-year-old woman with a giant malignant phyllodes tumor (PT) in her right breast, with maximum diameter of 20 cm. The core-needle and excisional biopsy specimens were diagnosed as suspicious for low-grade myofibroblastic sarcoma (LGMS). The subsequent total mastectomy with partial resection of the pectoral muscles showed predominance of stromal hypercellularity without an epithelial component. However, we diagnosed this as a malignant PT because focal areas showed a leaf-like pattern. In the case of large malignant PTs that exhibit stromal predominance, it can be difficult to distinguish between a pure sarcoma and malignant PT. It is important to thoroughly examine multiple sections from the view point of residual epithelial structure in morphological diagnosis.
Collapse
Affiliation(s)
- Miki Takenaka
- Department of Pathology, Kurume University School of Medicine, Kurume University Hospital, Kurume University, Kurume 830-0011, Japan.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Subramanian V, Takenaka M, Tiriveedhi V, Benshoff N, Yamamoto S, Gelman A, Patterson A, Mohanakumar T. 14 Administration of Antibodies to Self Antigens (Kα1 Tubulin and Collagen V) Results in Obliterative Bronchitis after Syngeneic Mouse Lung Transplantation. J Heart Lung Transplant 2012. [DOI: 10.1016/j.healun.2012.01.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
41
|
Fukami N, Ramachandran S, Takenaka M, Weber J, Subramanian V, Mohanakumar T. An obligatory role for lung infiltrating B cells in the immunopathogenesis of obliterative airway disease induced by antibodies to MHC class I molecules. Am J Transplant 2012; 12:867-76. [PMID: 22233464 PMCID: PMC3721353 DOI: 10.1111/j.1600-6143.2011.03917.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Using a murine model, we demonstrated that endobronchial administration of antibodies (Abs) to major histocompatibility complex (MHC) class I results in cellular infiltration, epithelial metaplasia, fibrosis and obstruction of the small airways (obliterative airway disease [OAD]) mediated predominantly by Th17 responses to self-antigens. This resembles bronchiolitis obliterans syndrome developed following human lung transplantation. Since B cells play a crucial role in induction of autoimmune responses, we defined the role of B cells and its antigen presenting properties in induction of OAD in this study. Anti-MHC class I was administered endobronchially in B(-/-) and wild-type mice. In contrast to wild type, B(-/-) animals did not demonstrate cellular infiltration, epithelial metaplasia and obstruction of airways following anti-MHC. Frequency of K-α1 tubulin and CollagenV-specific IL-17 cells was significantly decreased in B(-/-) mice. As expected, Abs against self-antigens and germinal center formation were not developed in B(-/-) mice. Thus, we conclude that B cells and its antigen presenting capacity play an important role in induction of immune responses to self-antigens and immunopathogenesis of OAD following the administration of anti-MHC. Therefore, strategies to block B-cell and its antigen presenting functions should be considered for preventing the development of chronic rejection.
Collapse
Affiliation(s)
- N. Fukami
- Department of Surgery, Washington University School of Medicine, St. Louis, MO 63101
| | - S. Ramachandran
- Department of Surgery, Washington University School of Medicine, St. Louis, MO 63101
| | - M. Takenaka
- Department of Surgery, Washington University School of Medicine, St. Louis, MO 63101
| | - J. Weber
- Department of Surgery, Washington University School of Medicine, St. Louis, MO 63101
| | - V. Subramanian
- Department of Surgery, Washington University School of Medicine, St. Louis, MO 63101
| | - T. Mohanakumar
- Department of Surgery, Washington University School of Medicine, St. Louis, MO 63101,Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63101
| |
Collapse
|
42
|
Tiriveedhi V, Takenaka M, Subramanian V, Gelman A, Patterson G, Mohanakumar T. 95 Antibodies to MHC Induce Autoimmunity Leading to Obliterative Airway Disease: Definition of Mechanisms. J Heart Lung Transplant 2012. [DOI: 10.1016/j.healun.2012.01.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
43
|
Takenaka M, Toh U, Seki N, Kawahara A, Hattori S, Iwakuma N, Yamaguchi R, Yano H, Shirouzu K, Kage M. 335 FOXP3 Expression in Tumor Cells Associated with the Prognosis in Breast Cancer Patients. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70401-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
44
|
Seki N, Takenaka M, Toh U, Kawahara A, Fujii T, Yamaguchi R, Yamana H, Yano H, Shirouzu K, Kage M. 284 Expression of Cancer-testis Antigens in Breast Cancer. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70351-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
45
|
Iwakuma N, Toh U, Grobmyer S, Koura K, Takenaka M, Otsuka H, Takahashi R, Shirouzu K. 75 The Potential of Targeting Nanoparticle for Breast Cancer Diagnosis. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70143-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
46
|
Ben Suleiman Y, Yoshida M, Nishiumi S, Tanaka H, Mimura T, Nobutani K, Yamamoto K, Takenaka M, Aoganghua A, Miki I, Ota H, Takahashi S, Matsui H, Nakamura M, Blumberg RS, Azuma T. Neonatal Fc receptor for IgG (FcRn) expressed in the gastric epithelium regulates bacterial infection in mice. Mucosal Immunol 2012; 5:87-98. [PMID: 22089027 PMCID: PMC3964614 DOI: 10.1038/mi.2011.53] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Neonatal Fc receptors for immunoglobulin (Ig)G (FcRn) assume a central role in regulating host IgG levels and IgG transport across polarized epithelial barriers. We have attempted to elucidate the contribution of FcRn in controlling Helicobacter infection in the stomach. C57BL/6J wild-type or FcRn(-/-) mice were infected with Helicobacter heilmannii, and gastric lesions, bacterial load and the levels of antigen-specific IgG in serum and gastric juice were analyzed. The elevated levels of anti-H. heimannii IgG in gastric juice were observed exclusively in wild-type mice but not in FcRn(-/-) mice. In contrast, an increase in lymphoid follicles and bacterial loads along with deeper gastric epithelium invasion were noted in FcRn(-/-) mice. C57BL/6J wild-type or FcRn(-/-) mice were also infected with Helicobacter pylori SS1, and the results of the bacterial load in stomachs of these mice and the anti-H. pylori IgG levels in serum and gastric juice were similar to those from H. heilmannii infection. Our data suggest that FcRn can be functionally expressed in the stomach, which is involved in transcytosis of IgG, and prevent colonization by H. heilmannii and the associated pathological consequences of infection.
Collapse
Affiliation(s)
- Y Ben Suleiman
- Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
| | - M Yoshida
- Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
,The Integrated Center for Mass Spectrometry, Kobe University Graduate School of Medicine, Kobe, Japan.
,Division of Metabolomics Research, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
| | - S Nishiumi
- Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
| | - H Tanaka
- Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
| | - T Mimura
- Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
| | - K Nobutani
- Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
| | - K Yamamoto
- Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
| | - M Takenaka
- Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
| | - A Aoganghua
- Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
| | - I Miki
- Department of Medical Pharmaceutics, Kobe Pharmaceutical University, Kobe, Japan.
| | - H Ota
- Department of Biomedical Laboratory Sciences, School of Health Sciences, Shinshu University School of Medicine, Nagano, Japan.
| | - S Takahashi
- Third Department of Internal Medicine, Kyorin University, Tokyo, Japan.
| | - H Matsui
- Kitasato Institute for Life Sciences and Graduate School of Infection Control Sciences, Kitsato University, Tokyo, Japan.
| | - M Nakamura
- Center for Clinical Pharmacy and Clinical Sciences, School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan.
| | - RS Blumberg
- Division of Gastroenterology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA.
| | - T Azuma
- Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
| |
Collapse
|
47
|
Hanagiri T, Takenaka M, Oka S, Shigematsu Y, Nagata Y, Shimokawa H, Uramoto H, Yamada S, Tanaka F. Prognostic significance of lymphovascular invasion for patients with stage I non-small cell lung cancer. Eur Surg Res 2011; 47:211-7. [PMID: 22025080 DOI: 10.1159/000333367] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2011] [Accepted: 08/15/2011] [Indexed: 02/04/2023]
Abstract
AIMS This study retrospectively investigated the clinical significance of lymphovascular invasion (LVI) following a complete resection for stage I non-small cell lung cancer (NSCLC). METHODS A total of 226 patients who underwent a complete resection for pathological stage I NSCLC were examined. RESULTS Lymphatic invasion was pathologically diagnosed as ly0 in 156 patients, ly1 in 65, and ly2 in 5 patients. The pathological vascular invasion was diagnosed as v0 in 178 patients, v1 in 35, v2 in 10, and v3 in 3 patients. The 5-year survival rate after surgery of the patients with and without lymphatic invasion was 76.8 and 90.6%, respectively. There was a significantly more unfavorable prognosis in patients with lymphatic invasion (p = 0.042). The 5-year survival rate of the patients with vascular invasion was also significantly more unfavorable (67.8%) than that of patients without vascular invasion (90.4%; p = 0.004). LVI was found to significantly correlate with tumor size and the presence of pleural invasion. CONCLUSION The LVI of NSCLC is a significant prognostic factor in patients with stage I tumors. In future clinical trials, it is necessary to evaluate the efficacy of adjuvant therapy for the selection of patients according to this criterion.
Collapse
Affiliation(s)
- T Hanagiri
- Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Toh U, Iwakuma N, Otsuka H, Takenaka M, Ogo E, Fujii T, Tanaka M, Shirouzu K. A multicenter phase II study of S-1 combined with irinotecan (CPT-11) for patients with advanced/recurrent breast cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e11528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
49
|
Tomita H, Muroi E, Takenaka M, Nishimoto K, Kakeya H, Ohno H, Miyazaki Y, Utani A. Rhizomucor variabilis infection in human cutaneous mucormycosis. Clin Exp Dermatol 2010; 36:312-4. [PMID: 21070336 DOI: 10.1111/j.1365-2230.2010.03956.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
50
|
Oka S, Hanagiri T, Takenaka M, Baba T, Yasuda M, Ono K, Uramoto H, Takenoyama M, Yasumoto K. [Surgical treatment for patients with descending necrotizing mediastinitis]. Kyobu Geka 2010; 63:1022-1025. [PMID: 21066840] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Descending necrotizing mediastinitis (DNM) originating from deep cervical infection is a rare and serious clinical condition with a high mortality rate. Clinical feature of 5 patients undergone surgical drainage for DNM, between 2006 and 2009 were assessed. There were 3 male and 2 female patients whose age ranged from 57 to 83 years old (mean 69.8). All 5 patients had no underlying disease except for 1 patient with severe dental caries. The primary infections of these patients were tonsillitis and pharyngitis. The mean duration from onset of symptom to the referral to our hospital was 14 days (ranged 2 to approximately 41). Two patients underwent cervical drainage for upper mediastinum, and 3 patients were required mediastinal drainage by thoracotomy. There was no post-operative death. Early and aggressive surgical drainage of the neck and mediastinum by a multidisciplinary team of surgeons is very important in the treatment of DNM.
Collapse
Affiliation(s)
- S Oka
- Second Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|